Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Large Volume Increase Following Analyst Upgrade

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) saw an uptick in trading volume on Wednesday after Needham & Company LLC raised their price target on the stock from $30.00 to $33.00. Needham & Company LLC currently has a buy rating on the stock. 1,343,090 shares traded hands during mid-day trading, an increase of […]

Related Keywords

China ,Piper Sandler ,Samuelc Blackman ,Day One Biopharmaceuticals Company Profile ,Jpmorgan Chase Co ,Securities Exchange Commission ,Day One Biopharmaceuticals Inc ,Quintet Private Bank Europe ,Quest Partners ,China Universal Asset Management Co ,Nasdaq ,Needham Company ,Goldman Sachs Group ,Exchange Traded Concepts ,Day One Biopharmaceuticals ,Get Free Report ,Exchange Commission ,Universal Asset Management ,Traded Concepts ,One Biopharmaceuticals Stock Down ,One Biopharmaceuticals ,Day One Biopharmaceuticals Daily ,Nasdaq Dawn ,Dawn ,Medical ,Stocks ,Technicals ,